Trials / Completed
CompletedNCT03809767
A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas
A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors or Lymphomas
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 107 (actual)
- Sponsor
- CStone Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1003 in subjects with advanced solid tumors or lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS1003 monoclonal antibody | CS1003 will be administered intravenously every 3 weeks. |
Timeline
- Start date
- 2018-10-29
- Primary completion
- 2021-08-30
- Completion
- 2022-06-13
- First posted
- 2019-01-18
- Last updated
- 2022-11-30
Locations
17 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03809767. Inclusion in this directory is not an endorsement.